Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label erenumab study in persistent post-traumatic headache after mild traumatic head injury
2018-003943-46Phase 2Completed
- Sponsor
- Dansk Hovedpinecenter
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erenumab in chronic post-traumatic headache (CPTHA), sponsored by Dansk Hovedpinecenter. Primary endpoint: Change in monthly average number of headache days with moderate or severe intensity. Started Nov 2018; status: completed.
02
Drugs
erenumab
03
Conditions
chronic post-traumatic headache (CPTHA)
Beyond the preview
Go deeper on 2018-003943-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003943-46.